MoonLake Immunotherapeutics (MLTX) announced positive topline Week 16 results from the Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis and reported second quarter 2026 financial results.
The company said IZAR-1 met all clinical endpoints at Week 16 for 60 mg sonelokimab. MoonLake ended the quarter with $537.0 million in cash, cash equivalents and short-term marketable debt securities, and reported a net loss of $61.8 million.
- 42.1% of patients treated with sonelokimab 60 mg with induction achieved ACR50 at Week 16.
- Key secondary results included ACR20 of 66.5%, MDA of 41.2% and PASI90 of 61% in patients with concomitant skin involvement.
- Research and development expenses were $50.2 million for the three months ended June 30, 2026.
- General and administrative expenses were $11.4 million for the quarter.
- MoonLake expects cash runway to mid-2028 and said up to $400 million remains available through its Hercules Capital debt facility.
- Upcoming milestones include an expected HS BLA submission by the end of September 2026 and expected IZAR-2 enrollment completion in Q3 2026.
$MLTX Insider Trading Activity
$MLTX insiders have traded $MLTX stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $MLTX stock by insiders over the last 6 months:
- DA SILVA JORGE SANTOS (Chief Executive Officer) has made 0 purchases and 5 sales selling 300,000 shares for an estimated $5,755,301.
- KRISTIAN REICH (Chief Scientific Officer) has made 0 purchases and 8 sales selling 263,353 shares for an estimated $5,123,154.
- MATTHIAS BODENSTEDT (Chief Financial Officer) has made 0 purchases and 7 sales selling 160,870 shares for an estimated $3,198,501.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MLTX Hedge Fund Activity
We have seen 84 institutional investors add shares of $MLTX stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BVF INC/IL removed 3,750,000 shares (-19.0%) from their portfolio in Q1 2026, for an estimated $69,900,000
- MPM BIOIMPACT LLC added 1,811,082 shares (+inf%) to their portfolio in Q1 2026, for an estimated $33,758,568
- DEEP TRACK CAPITAL, LP added 1,798,792 shares (+39.0%) to their portfolio in Q1 2026, for an estimated $33,529,482
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,500,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $27,960,000
- WEISS ASSET MANAGEMENT LP added 1,375,367 shares (+413.1%) to their portfolio in Q1 2026, for an estimated $25,636,840
- JANE STREET GROUP, LLC removed 1,228,523 shares (-73.0%) from their portfolio in Q1 2026, for an estimated $22,899,668
- CITADEL ADVISORS LLC added 942,838 shares (+247.5%) to their portfolio in Q1 2026, for an estimated $17,574,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
